Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Jagiello-Gruszfeld, A.
Tjulandin, Sergei S.
Dobrovolskava, N.
Manikhas, A.
Pienkowski, T.
Knott, A.
DeSilvio, M.
Oliva, C.
机构：
[1] Nzoz Onko Med, Olsztyn, Poland
[2] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia
[3] Russian Sci Ctr Roentgeno Radiol, Moscow, Russia
[4] St Petersburg City Oncol Dispensery, St Petersburg, Russia
[5] Inst Marii Sklodowskiej Curie, Centrum Onkol, Warsaw, Poland
[6] GlaxoSmithKline Res & Dev Ltd, London, England
[7] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246S / 246S
页数：1
相关论文
共 50 条
  • [31] Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+metastatic breast cancer (MBC): A quality-of-life (QOL) analysis
    Sherif, B. N.
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
    Bahl, Amit
    Braybrooke, Jeremy
    Bravo, Alicia
    Foulstone, Emily
    Ball, Jessica
    Churn, Mark
    Dubey, Sidharth
    Spensley, Saiqa
    Bowen, Rebecca
    Waters, Simon
    Riddle, Pippa
    Wheatley, Duncan
    Stephens, Peter
    Mansi, Janine
    Bezecny, Pavel
    Madhusudan, Srinivasan
    Verrill, Mark
    Markham, Alison
    Pearson, Sylvia
    Wilson, William
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND WEEKLY PACLITAXEL (T) AS FIRST-LINE TREATMENT IN METASTATIC BREAST CANCER (MBC)
    Badalamenti, Giuseppe
    Valerio, Maria Rosaria
    Rinaldi, Gaetana
    Arcara, Carlo
    Cicero, Giuseppe
    Vizzini, Laura
    Travagliato, Maria Grazia
    Intrivici, Chiara
    Russo, Antonio
    Gulotta, Gaspare
    Gebbia, Nicola
    Fulfaro, Fabio
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [34] IMP321 and weekly paclitaxel as first-line chemo-immunotherapy for metastatic breast cancer (MBC)
    Gutierrez, Maya
    Brignone, Chrystelle
    Grygar, Caroline
    Marcu, Manon
    Triebel, Frederic
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 873 - 873
  • [35] Weekly paclitaxel (T) and cisplatin (P) in patients (Pts) with metastatic breast cancer (Mbc) previously treated with antraciclines (A).
    Martinez, LC
    Campelo, RG
    Curbera, GA
    Ayerbes, MV
    Novoa, SA
    Hernández, PA
    Aparicio, LA
    ANNALS OF ONCOLOGY, 2000, 11 : 38 - 38
  • [36] Weekly paclitaxel, doxorubicin, and carboplatin in the first-line treatment of patients with metastatic breast cancer
    Hainsworth, JD
    Burris, HA
    Greco, FA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 13 - 13
  • [37] Experience and impact of alopecia in patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry.
    Mason, Ginny
    Mayer, Musa
    Swain, Sandra M.
    Kaufman, Peter
    Tripathy, Debu
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Yardley, Denise A.
    Brufsky, Adam
    Rugo, Hope S.
    Cobleigh, Melody A.
    Chu, Laura Kay
    Antao, Vincent P.
    Morris, Anne
    Yoo, Bongin
    Jahanzeb, Mohammad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [38] A Real-world Analysis of the Treatment of HER2+Metastatic Breast Cancer (mBC) Beyond First-line HER2-directed Therapies
    DeSouza, K.
    Zammit, R.
    Bloomfield, D.
    Simcock, R.
    Sinha, R.
    Westwell, S.
    Moss, C.
    Moss, A.
    Sham, J.
    Patel, G.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E108 - E108
  • [39] Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Gradishar, W.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A.
    Manikhas, G.
    Clawsons, A.
    Bhars, P.
    EJC SUPPLEMENTS, 2008, 6 (07): : 172 - 172
  • [40] Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+metastatic breast cancer (MBC)
    Brufsky, Adam
    Yardley, Denise Aysel
    Yood, Marianne Ulcickas
    Tripathy, Debu
    Kaufman, Peter Andrew
    Mayer, Musa
    Feng, Shibao
    Abidoye, Oyewale O.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345